Skip to content

Study · Measured the body's own peptide · 2026

3 results

Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?

Filibeli BE, Dedemoglu F, Garipçin P, Bulut S, Başok Bİ, Kizildağ S, Dündar B, Çatli G

Archives of endocrinology and metabolism7 Apr 2026

PMID41945630 (opens in a new tab)PMCIDPMC13055642 (opens in a new tab)DOI10.20945/2359-4292-2026-0031 (opens in a new tab)PepBankPUB-41945630
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

ObjectiveMOTS-c is a mitochondria-derived peptide associated with reduced insulin resistance and obesity. The m.1382A>C polymorphism of the MOTS-c gene is linked to an increased risk of type 2 diabetes in men. However, no studies have explored the relationship between this polymorphism and MOTS-c levels in adolescents with polycystic ovary syndrome (PCOS). This study aimed to investigate the differences in MOTS-c levels between adolescents diagnosed with PCOS and those without PCOS, as well as the associations with metabolic parameters. The association between the MOTS-c gene polymorphism and serum MOTS-c levels in adolescents with PCOS was also evaluated.Subjects and methodsAdolescents aged 12-18 diagnosed with PCOS were recruited based on irregular menstrual cycles and clinical/biochemical hyperandrogenism, excluding other conditions. The control group consisted of adolescents with regular menstruation. Serum MOTS-c levels were measured using ELISA, and the m.1382A>C polymorphism was analyzed by sequencing.ResultsThe study included 121 adolescents with PCOS and 125 healthy controls. The mean serum MOTS-c levels in the PCOS group were higher than in the control group; however, this difference did not reach statistical significance (p = 0.059). There was no significant association between MOTS-c levels and anthropometric or metabolic parameters within the PCOS group (p > 0.05). All participants had the wild-type (A/A) genotype for the m.1382A>C polymorphism.ConclusionResultsindicate that the MOTS-c gene (m.1382A>C) polymorphism shows no significant association with PCOS, and serum MOTS-c levels are comparable between individuals with PCOS and healthy controls, suggesting that MOTS-c may have a minor involvement in the pathophysiology of PCOS.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In adolescents with PCOS, serum levels of the body's own MOTS‑c were higher than in controls, but the difference was not statistically significant.

    In plain wordsAdolescents with PCOS did not have clearly different levels of the body's own MOTS‑c than healthy adolescents.

    Peptide
    MOTS-c
    Outcome
    No significant changeSerum MOTS-c in PCOS versus controls
    Study

    n = 246

    Comparator
    Healthy controls
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    The mean serum MOTS-c levels in the PCOS group were higher than in the control group; however, this difference did not reach statistical significance (p = 0.059).
    2 context sentences
    Summary · context
    The study included 121 adolescents with PCOS and 125 healthy controls.
    Summary · context
    Adolescents aged 12-18 diagnosed with PCOS were recruited based on irregular menstrual cycles and clinical/biochemical hyperandrogenism, excluding other conditions.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    All participants had the wild-type A/A genotype for the MOTS‑c m.1382A>C polymorphism, so no association with PCOS was found.

    In plain wordsAll adolescents had the common gene form for the body's own MOTS‑c, so no link between this gene change and PCOS was seen.

    Peptide
    MOTS-c
    Outcome
    Not applicableMOTS-c m.1382A>C polymorphism genotype
    Study

    n = 246

    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    All participants had the wild-type (A/A) genotype for the m.1382A>C polymorphism.
    2 context sentences
    Summary · context
    indicate that the MOTS-c gene (m.1382A>C) polymorphism shows no significant association with PCOS, and serum MOTS-c levels are comparable between individuals with PCOS and healthy controls, suggesting that MOTS-c may have a minor involvement in the pathophysiology of PCOS.
    Summary · context
    Adolescents aged 12-18 diagnosed with PCOS were recruited based on irregular menstrual cycles and clinical/biochemical hyperandrogenism, excluding other conditions.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    Within the PCOS group, MOTS‑c levels showed no significant association with anthropometric or metabolic parameters.

    In plain wordsAmong adolescents with PCOS, the body's own MOTS‑c was not linked to body measures or metabolic tests.

    Peptide
    MOTS-c
    Outcome
    No significant changeMOTS-c association with anthropometric and metabolic parameters in PCOS
    Study

    n = 121

    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    There was no significant association between MOTS-c levels and anthropometric or metabolic parameters within the PCOS group (p > 0.05).
    1 context sentence
    Summary · context
    Adolescents aged 12-18 diagnosed with PCOS were recruited based on irregular menstrual cycles and clinical/biochemical hyperandrogenism, excluding other conditions.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.